In a report released on February 7, Heiko Ihle from H.C. Wainwright reiterated a Buy rating on UR-Energy (URG – Research Report), with a price ...

H.C. Wainwright reiterated a Buy rating and a price target of $18.00 on Enanta Pharmaceuticals (NASDAQ:ENTA) shares, significantly above the current price of $4.90. The stock is trading near its ...

H.C. Wainwright increased its price target on Corcept Therapeutics (NASDAQ:CORT) shares to $115 from the previous $80, while ...

HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research ...

H.C. Wainwright raised the firm’s price target on NextTrip (NTRP) to $5 from $2.50 and keeps a Neutral rating on the shares after the company ...

HC Wainwright reissued their buy rating on shares of Immix Biopharma (NASDAQ:IMMX – Free Report) in a report released on ...

We recently compiled a list of the 10 Trending AI Stocks That Analysts Are Monitoring. In this article, we are going to take ...

Fintel reports that on February 7, 2025, HC Wainwright & Co. initiated coverage of Vertical Aerospace (NYSE:EVTL) with a Buy recommendation. As of January 28, 2025, the average one-year price ...

H.C. Wainwright & Co., LLC, announced its #1 Ranking by transaction volume for the calendar year of 2024, maintaining the Firm’s top position for 11 consecutive years in PlacementTracker's Market ...

Tuesday, H.C. Wainwright reaffirmed its Buy rating on Northern Dynasty Minerals (NYSE:NAK) with a steady price target of $1.30, representing significant upside from the current trading price of $0.65.

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (LSE:0VRQ) with a Buy recommendation. There are 575 funds or institutions reporting positions ...